Animal models of myasthenia gravis

Clinical Immunology

Volumn 94, Issue 2, 2000, Pages 75-87

  Christadoss, Premkumar ^a   Poussin, Mathilde ^a   Deng, Caishu ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Autoimmunity; Cytokines; MHC class II; Myasthenia gravis; Pathogenesis; Specific therapy; T cell epitope

Indexed keywords

ALPHA INTERFERON; CD28 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN GP 39; HLA B7 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; DNA POLYMORPHISM; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MYASTHENIA GRAVIS; NONHUMAN; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; T LYMPHOCYTE RECEPTOR GENE; TH2 CELL; TORPEDO CALIFORNICA;

EID: 0033955430     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.1999.4807     Document Type: Review

References (109)

1. Fambrough C. M., Drachman D. B., Satyamurti S. Neuromuscular junction in myasthenia gravis: Decreased acetylcholine receptors. Science. 182:1973;293-295.
2. Kao I., Drachman D. B. Myasthenic immunoglobulin accelerates receptor degradation. Science. 196:1977;527-529.
3. Heinemann S., Bevan S., Kullerg R., Lindstrom J., Rice J. Modulation of acetylcholine receptor by antibody against the receptor. Proc. Natl. Acad. Sci. USA. 7:1977;3090-3094.
4. Drachman D. B., Admas R. N., Stanley E. F., Pestronk A. Mechansims of acetylcholine receptor loss in myasthenia gravis. J. Neurol. Neurosurg. Psychiatry. 43:1980;601-610.
5. Almon R. R., Andrew C. G., Appel S. H. Serum globulin in myasthenia gravis: Inhibition of α-bungarotoxin binding to acetylcholine receptors. Science. 186:1974;55-57.
6. Patrick J., Lindstrom J. M. Autoimmune response to acetylcholine receptor. Science. 180:1973;871-872.
7. Lennon V., Lindstrom J., Seybold M. E. Experimental autoimmune myasthenia (EAMG): A model of myasthenia gravis in rats and guinea pigs. J. Exp. Med. 141:1975;1365-1375.
8. Fuchs S. D., Neiro D., Tarrab-Hazdai R., Yaar G. Strain differences in the autoimmune response of mice to acetylcholine receptors. Nature. 263:1976;329-330.
9. Christadoss P., Lennon V. A., Lambert E. H., David C. S. Genetic control of experimental autoimmune myasthenia gravis in mice. T and B Lymphocytes: Recognition and function. 1979;Academic Press, New York. p. 249.
10. Berman P. W., Patrick J. Linkage between the frequency of muscular weakness and loci that regulate immune responsiveness in murine experimental autoimmune myasthenia gravis. J. Exp. Med. 152:1980;507-520.
11. Christadoss P., Lennon V. A., Krco C. J., Lambert E. H., David C. S. Genetic control of autoimmunity to acetylcholine. Ann. NY Acad. Sci. 377:1981;258-277.
12. Christadoss P. C5 gene influences the development of murine myasthenia gravis. J. Immunol. 140:1988;2589-2592.
13. Shenoy M., Wu B., Kaul R., Goluszko E., David C., Christadoss P. Possible linkage of myasthenia gravis susceptibility in RIII/SJ mice to the genomic deletion of chromosomal segment coding the T cell receptor VI3 genes. Zouali M., Fundamental and Experimental Aspect of Autoimmunity. 1994;213-220 Springer-Verlag, Berlin, New York.
14. Gu D., Wogensen L. L., Calcutt N. A., Xia C., Zhu X., Merlie J. P., Fox H. S., Lindstrom J., Powell H., Saretnick N. Myasthenia gravis-like syndrome induced by expression of γ-IFN in the neuromuscular junction. J. Exp. Med. 181:1995;547-557.
15. Toyka K. N., Drachman D. B., Griffin D. E., Pestronk A., Winkelstein J. A., Fishbeck K. H., Kao J. Myasthenia gravis: Study of humoral immune mechanisms by passive transfer to mice. N. Engl. J. Med. 296:1977;125-131.
16. Richman D. P., Gomez C. M., Berman P. W., Burres S. A., Fitch F. W., Amason B. G. Monoclonal anti-acetylcholine receptor antibodies can cause experimental myasthenia. Nature. 286:1980;738-739.
17. Schonbeck S., Padberg F., Hohlfeld R., Wekerle H. Transplantation of thymic autoimmune microenvironment to severe combined immunodeficiency mice. J. Clin. Invest. 90:1992;245-250.
18. Wang Z.-Y., Karachunski P. I., Howard J. F. Jr., Conti-Fine B. M. Myasthenia in SCID mice grafted with myasthenic patient lymphocytes. Neurology. 52:1999;484-497.
19. Christadoss P., Lindstrom J. M., Talal N., Duvic C. R., Kalantri A., Shenoy M. Immune response gene control of lymphocyte proliferation induced by acetylcholine receptor-specific helper factor derived from lymphocytes of myasthenic mice. J. Immunol. 137:1986;1845-1849.
20. Christadoss P., Lindstrom J., Munro S., Talal N. Muscle acetylcholine receptor loss in murine experimental autoimmune myasthenia gravis: Correlated with cellular, humoral and clinical responses. J. Neuroimmunol. 8:1985;29-41.
21. Lindstrom J. M., Seybold M. E., Lennon V. A., Whittingnam S., Duane D. D. Antibody to acetylcholine receptor in myasthenia gravis. Neurology. 26:1976;1054-1059.
22. Lefvert A. K., Bengstrom K., Matell G., Osterman P. O., Pirskanen R. Determination of acetylcholine receptor antibodies in myasthenia gravis clinical usefulness and pathogenic implications. J. Neurol. Neurosurg. Psychiatry. 4:1978;394-403.
23. Vincent A., Newsome-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: Results in 153 validated cases and 2967 diagnostic assays. J. Neurol. Neurosurg. Psychiatry. 48:1985;1246-1252.
24. Engel A. G., Lambert E. H., Howard F. H. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: Ultrastructural and light microscopic localization and electrophysiologic correlation. Mayo Clin. Proc. 52:1977;267-280.
25. Sahashi S., Engel A. G., Lindstrom J., Lambert E. H., Lennon V. A. Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis. J. Neuropathol. Exp. Neurol. 37:1978;212-223.
26. Christadoss P., Lindstrom J. M., Melvold R. W., Talal N. Mutation at I-A beta chain prevents experimental autoimmune myasthenia gravis. Immunogenetics. 21:1985;33-38.
27. Kaul R., Shenoy M., Goluszko E., Christadoss P. Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. J. Immunol. 152:1994;3152-3157.
28. Christadoss P. Immunogenetics of experimental autoimmune myasthenia gravis. Crit. Rev. Immunol. 9:1989;247-278.
29. Bell J., Rassenti L., Smoot S., Smith K., Newby C., Hohlfeld R., Toyka K., McDevitt H., Steinman L. HLA-DQ beta-chain polymorphism linked to myasthenia gravis. Lancet. 1:1986;1058-1060.
30. Hjelmström P., Giscombe R., Lefvert A. K., Pirskanen R., Kockum I., Landin-Olsson M., Sanjeevi C. B. Polymorphic amino acid domains of the HLA-DQ molecule are associated with disease heterogeneity in myasthenia gravis. J. Neuroimmunol. 65:1996;125-131.
31. Hjelmström P., De Weese-Scott C., Penzotti J. E., Lybrand T. P., Sanjeevi C. B. Structural differences between HLA-DQ molecules associated with myasthenia gravis characterized by molecular modeling. J. Neuroimmunol. 85:1998;102-105.
32. Hjelmström P., Sanjeevi C. B. Molecular mechanisms of MHC associations with myasthenia gravis. Christadoss P., Myasthenia Gravis: Disease Mechanisms and Immunointervention. 1999;Narosa Publishing House, New Delhi.
33. Christadoss P., Lennon V. A., David C. S. Genetic control of experimental autoimmune myasthenia gravis in mice. III. Ia molecules mediate cellular immune responsiveness to acetylcholine receptors. J. Immunol. 128:1982;1141-1144.
34. Hohlfeld R., Conti-Tronconi B., Kalies I., Bertrams J., Toyka K. V. Genetic restriction of autoreactive acetylcholine receptor-specific T lymphocytes in myasthenia gravis. J. Immunol. 135:1985;2393-2399.
35. Brocke S., Brautbar C., Steinman L., Abramsky O., Rothbard J., Neumann D., Fuchs S., Mozes E. In vitro proliferative response and antibody titers specific to human acetylcholine receptor in patients with myasthenia gravis and relation to HLA class II genes. J. Clin. Invest. 82:1988;1894-1900.
36. Christadoss P., Dauphinee M. J. Immunotherapy for myasthenia gravis: A murine model. J. Immunol. 136:1986;2437-2440.
37. Ahlberg R., Yi Q., Matell R., Swerup G., Rieber P., Reithmuller G., Holm G., Lafvert A. K. Clinical improvement of myasthenia gravis by treatment with a chimeric anti-CD4 monoclonal antibody. Ann. NY Acad. Sci. 681:1993;552-555.
38. Meinl E., Klinkert W. E., Wekerle H. The thymus in myasthenia gravis: Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat. Am. J. Pathol. 139:1991;995-1008.
39. Schluep M., Willcox N., Vincent A., Dhoot G. K., Newsom-Davis J. Acetylcholine receptors in human thymic myoic cells in situ: An immunohistological study. Ann. Neurol. 22:1987;212-222.
40. Wekerle H., Ketelsen U. P. Intrathymic pathogenesis and dual genetic control of myasthenia gravis. Lancet. 1:1977;678-680.
41. Kornstein M. J., Asher O., Fuchs S. Acetylcholine receptor alpha-subunit and myogenin mRNAs in thymus and thymomas. Am. J. Pathol. 146:1995;1320-1324.
42. Kirchner T., Tzartos S., Hoppe F., Schalke B., Wekerle H., Müller-Mermelink H. K. Pathogenesis of myasthenia gravis: Acetylcholine receptor-related antigenic determinants in tumor-free thymuses and thymic epithelial tumors. Am. J. Pathol. 130:1988;268-280.
43. Marx A., O'Connor R., Geuder K. I., Hoppe F., Schalke B., Tzartos S., Kalies I., Kirchner T., Müller-Hermelink H. K. Characterization of a protein with an acetylcholine receptor epitope from myasthenia gravis-associated thymomas. Lab. Invest. 62:1990;279-286.
44. Andretta F., Baggi F., Antozzi C., Torchiana E., Bernasconi P., Simoncini O., Cornelio F., Mantegazza R. Acetylcholine receptor alpha-subunit isoforms are differentially expressed in thymuses from myasthenic patients. Am. J. Pathol. 150:1997;341-348.
45. Sommer N., Willcox N., Harcourt G. C., Newsom-Davis J. Myasthenic thymus and thymoma re-selectively enriched in acetylcholine receptor-reactive T cells. Ann. Neurol. 28:1990;312-319.
46. Gutshe, S, Wilish, A, Hoffacker, V, Schultz, A, Tzartos, S, Nix, W, Schalke, B, Schneider, C, Müller-Mermelink, H.-K, and, Marx, A, Expression of the acetylcholine receptor α subunit gene is associated with paraneoplastic myasthenia gravis in mixed thymoma, In, Myasthenia Gravis: Mechanisms of Disease and Immunointervention, (, P. Christadoss, Ed.), Narosa Publishing House, New Delhi, in press.
47. Marx, A, Wilisch, A, Gutsche, S, Hoffacker, V, Schultz, A, Tzartos, S, Nix, W, Schalke, B, Schneider, C, and, Müller-Hermelink, H.-K, Low levels of acetylcholine receptor delta-subunit message and protein in human thymus suggests the occurrence of "triplet receptors" in thymic myoid cells, In, Myasthenia Gravis: Mechanisms of Disease and Immunointervention, (, P. Christadoss, Ed.), Narosa Publishing House, New Delhi, in press.
48. Tzartos S. J., Barkas T., Cung M. T., Mamalaki A., Marraud M., Orlewski P., Papanastasiou D., Sakarellos C., Sakarellos-Daitsiotis M., Tsantili P., Tsikaris V. Anatomy of the antigenic structure of a large membrane antigen, the muscle-type nicotinic acetylcholine receptor. Immunol. Rev. 163:1998;89-120.
49. Conti-Tronconi B. M., McLane K. E., Raftery M. A., Grando S. A., Protti M. P. The nicotinic acetylcholine receptor: Structure and autoimmune pathology. Crit. Rev. Biochem. Mol. Biol. 29:1994;69-123.
50. Vincent A., Willcox N. Characterization of specific T cells in myasthenia gravis. Immunol. Today. 15:1994;41-42.
51. Vincent A. Aetiological factors in development of myasthenia gravis. Adv. Neuroimmunol. 4:1994;355-371.
52. Krolick K. A., Zoda T. E., Thompson P. A. Examination of characteristics that may distinguish disease-causing from benign AChR-reactive antibodies in experimental autoimmune myasthenia gravis. Adv. Neuroimmunol. 4:1994;475-493.
53. Deng C., Goluszko E., Baron S., Christadoss P. Interferon α therapy is effective in suppressing the clinical experimental myasthenia gravis. J. Immunol. 157:1996;5675-5682.
54. Moiola L., Galbiati F., Martino G., Amadio S., Brambilla E., Comi G., Vincent A., Grimaldi L. M., Adorini L. IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease. Eur. J. Immunol. 28:1998;2487-2497.
55. Balasa B., Deng C., Lee J., Bradley L. M., Dalton D. K., Christadoss P., Sarvetnick N. Interferon γ (IFN-γ) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J. Exp. Med. 186:1997;385-391.
56. Christadoss P., Lennon V. A., David C. S. Genetic control of experimental autoimmune myasthenia gravis in mice. J. Immunol. 123:1979;2540-2543.
57. Shenoy M., Oshima M., Atassi M. Z., Christadoss P. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region alpha 146-162 of acetylcholine receptor. Clin. Immunol. Immunopathol. 66:1993;230-238.
58. Kaul R., Shenoy M., Christadoss P. The role of major histocompatibility complex genes in myasthenia gravis and experimental autoimmune myasthenia gravis pathogenesis. Adv. Neuroimmunol. 4:1994;387-402.
59. + T cells are essential to induce experimental autoimmune myasthenia gravis. J. Exp. Med. 184:1996;349-356.
60. Shenoy M., Kaul R., Goluszko E., David C., Christadoss P. Effect of MHC class I and CD8 cell deficiency on experimental autoimmune myasthenia gravis pathogenesis. J. Immunol. 153:1994;5330-5335.
61. + T cells in myasthenia gravis: Epitope repertoire and T cell receptor gene usage. Christadoss P., Myasthenia Gravis: Disease Mechanisms and Immunointervention. 1999;Narosa Publishing House, New Delhi.
62. Waldor M. K., Sriram S., McDewitt H. O., Steinman L. In vivo therapy with monoclonal anti-I-A antibody suppresses immune response to acetylcholine receptor. Proc. Natl. Acad. Sci. USA. 80:1983;2713-2717.
63. Infante A. J., Thompson P. A., Krolick K. A., Wall K. A. Determinant selection in murine experimental autoimmune myasthenia gravis: Effect of the bml2 mutation on T cell recognition of acetylcholine receptor epitopes. J. Immunol. 146:1991;2977-2982.
64. Yang B., McIntosh K. R., Drachman D. B. How subtle differences in MHC class II affect the severity of experimental autoimmune myasthenia gravis. Clin. Immunol. Immunopathol. 86:1998;45-58.
65. + cells sensitized to nicotinic acetylcholine receptor. J. Immunol. 147:1991;1484-1491.
66. bml2 mutation influences susceptibility to experimental autoimmune myasthenia gravis: A study in homozygous and heterozygous mice. Scand. J. Immunol. 42:1995;215-225.
67. b on binding with and antigen presentation of Torpedo acetylcholine receptor α-chain peptide 146-162. J. Immunol. 154:1995;5245-5254.
68. Raju R., Zhan W.-Z., Karachunski P., Conti-Fine B., Sieck G. C., David C. Polymorphism at the HLA-DQ locus determines susceptibility to experimental autoimmune myasthenia gravis. J. Immunol. 160:1998;4169-4174.
69. Shenoy M., Kaul R., Goluszko E., Christadoss P. The pathogenic role of acetylcholine receptor α chain T cell epitope within region 146-162 in the development of experimental autoimmune myasthenia gravis in C57BL6 mice. Clin. Immunol. Immunopathol. 73:1994;338-343.
70. Oshima M., Ashizawa T., Pollack M., Atassi M. Z. Autoimmune T cell recognition of human acetylcholine receptor: The sites of T cell recognition in myasthenia gravis on the extracellular part of the α subunit. Eur. J. Immunol. 20:1990;2563-2569.
71. Krco C. J., David C. S., Lennon V. A. Mouse T lymphocyte response to acetylcholine receptor determined by T cell receptor for antigen Vβ gene products recognizing Mls-1α J. Immunol. 147:1991;3303-3305.
72. Infante A. J., Levcovitz H., Gordon V., Wall K. A., Thompson P. A., Krolick K. A. Preferential use of a T cell receptor Vβ gene by acetylcholine receptor reactive T cells from myasthenia gravis-susceptible mice. J. Immunol. 148:1992;3385-3390.
73. Aime-Sempe C., Cohen-Kaminsky S., Bruand C., Klingel-Schmitt I., Truffault F., Berrih-Aknin S. In vivo preferential usage of TCR V beta 8 in Torpedo acetylcholine receptor immune response in the murine experimental model of myasthenia gravis. J. Neuroimmunol. 58:1995;191-200.
74. Kaul R., Wu B., Goluszko E., Deng C., Dedhia V., Nabozny G. H., David C. S., Rimm I. J., Shenoy M., Haqqi T. M., Christadoss P. Experimental autoimmune myasthenia gravis in B10.BV8S2 transgenic mice: Preferential usage of TCRAV1 gene by lymphocytes responding to acetylcholine receptor. J. Immunol. 158:1997;6006-6012.
75. b strains. J. Immunol. 154:1995;3603-3610.
76. Melms A., Oksenberg J. R., Malcherek G., Schoepfer R., Miiller C. A., Lindstrom J., Steinman L. T-cell receptor gene usage of acetylcholine receptor-specific T-helper cells. Ann. NY Acad. Sci. 681:1993;313-314.
77. Dedhia V., Goluszko E., Wu B., Deng C., Christadoss P. The effect of B cell deficiency on the immune response to acetylcholine receptor and the development of experimental autoimmune myasthenia gravis. Clin. Immunol. Immunopathol. 87:1998;266-275.
78. Li H., Fu-Dong S., Bing H., Bakheit M., Wahren B., Berglöf A., Sandtedt K., Link H. Experimental autoimmune myasthenia gravis induction in B cell-deficient mice. Int. Immunol. 10:1998;1359-1365.
79. Shi F.-D., He B., Li H., Matusevicius D., Link H., Ljunggren H.-G. Differential requirements for CD28 and CD40 ligand in the induction of experimental autoimmune myasthenia gravis. Eur. J. Immunol. 28:1998;3587-3593.
80. McIntosh K. R., Linsley P. S., Bacha P. A., Drachman D. B. Immunotherapy of experimental autoimmune myasthenia gravis: Selective effects of CTLA4Ig and synergistic combination with an IL2-diphtheria toxin fusion protein. J. Neuroimmunol. 87:1998;136-146.
81. Shenoy M., Baron S., Wu B., Goluszko E., Christadoss P. IFN-α treatment suppresses the development of experimental autoimmune myasthenia gravis. J. Immunol. 154:1995;6203-6208.
82. Chung Y. H., Shong Y. K. Development of thyroid autoimmunity after administration of recombinant human interferon-a 2b for chronic viral hepatitis. Am. J. Gastroenterol. 88:1993;244.
83. Andre P., Brauns S., Passaquin A. C., Coupin G., Barthaleyns T., Warker J. M., Paindron R. Rat interferon enhances the expression of acetylcholine receptors in rat myotubes in culture. J. Neurosci. Res. 19:1988;297.
84. Zhang G.-X., Xiao B.-G., Bai X.-F., van Der Meide P. H., Om A., Link H. Mice with IFN- γ receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J. Immunol. 162:1999;3775-3781.
85. 2-type immune response in rats. J. Immunol. 162:1999;7189-7197.
86. Ozmen L., Roman D., Fountoulakis M., Schmid G., Ryffel B., Garotta G. Experimental therapy of systemic lupus erythematosus: The treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis. Eur. J. Immunol. 25:1995;6-12.
87. Haas C., Ryffel B., Le Hir M. IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/lpr mice. J. Immunol. 158:1997;5484-5491.
88. Haas C., Ryffel B., Le Hir M. IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB × NZW) F1 mice. J. Immunol. 160:1998;3713-3718.
89. 2 imbalance. J. Immunol. 161:1998;234-240.
90. 2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis. J. Immunol. 161:1998;2856-2862.
91. + epitope sequences of the acetylcholine receptor. J. Neuroimmunol. 95:1999;73-84.
92. Huang D., Xia S., Zhou Y., Pirskanen R., Liu L., Lefvert A. K. No evidence for interleukin-4 gene conferring susceptibility to myasthenia gravis. J. Neuroimmunol. 92:1998;208-211.
93. Wu B., Deng C., Goluszko E., Christadoss P. Tolerance to a dominant T cell epitope in the acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravis. J. Immunol. 159:1997;3016-3023.
94. Karachunki P. I., Ostlie N. S., Okita D. K., Garman R., Conti-Fine B. M. Subcutaneous administration of T-epitope sequences of the acetylcholine receptor prevents experimental myasthenia gravis. J. Neuroimmunol. 93:1999;108-121.
95. Wang Z. Y., Qiao J., Link H. Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J. Neuroimmunol. 44:1993;209-214.
96. 1-like cells and up-regulation of TGF-beta mRNA in mononuclear cells. Ann. NY Acad. Sci. 778:1996;273-287.
97. Wang Z. Y., Link H., Ljungdahl A., Hojeberg B., Link J., He B., Qiao J., Melms A., Olsson T. Induction of interferon-γ, interleukin-4, and transforming growth factor-β in rats orally tolerized against experimental autoimmune myasthenia gravis. Cell. Immunol. 157:1994;353-368.
98. Okumura S., Mclntosh K., Drachman D. B. Oral administration of acetylcholine receptor: Effects on experimental myasthenia gravis. Ann. Neurol. 36:1994;704-713.
99. Drachman D. B., Okumura S., Adams R. N., McIntosh K. R. Oral tolerance in myasthenia gravis. Ann. NY Acad. Sci. 778:1996;258-272.
100. Baggi, F, Andreetta, F, Caspani, E, Milani, M, Simonicini, O, Longhi, R, Cornelio, F, Mantegazza, R, and, Antozzi, C, In, Myasthenia Gravis: Disease Mechanism and Immunointervention, (, P. Christadoss, Ed.), Narosa Publishing House, New Delhi, in press.
101. Ma C. G., Zhang G. X., Xiao B. G., Link J., Olsson T., Link H. Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor. J. Neuroimmunol. 58:1995;51-60.
102. Shi F. D., Bai X. F., Li H. L., Huang Y. M., Van Der Meide P. H., Link H. Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): Induction of protective tolerance in primed animals. Clin. Exp. Immunol. 11:1998;506-512.
103. Karachunski P. I., Ostlie N. S., Okita D. K., Conti-Fine B. M. Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences. J. Clin. Invest. 100:1997;3027-3035.
104. Zhang G. X., Shi F. D., Zhu J., Xiao B. G., Levi M., Wahren B., Yu L. Y., Link H. Synthetic peptides fail to induce nasal tolerance to experimental autoimmune myasthenia gravis. J. Neuroimmunol. 85:1998;96-101.
105. Barchan D., Asher O., Tzartos S. J., Fuchs S., Souroujon M. C. Modulation of the anti-acetycholine receptor response and experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor. Eur. J. Immunol. 28:1998;616-624.
106. Barchan D., Souroujon M. C., Im S.-H., Antozzi C., Fuchs S. Antigen-specific modulation of experimental myasthenia gravis: Nasal tolerization with recombinant fragments of the human acetylcholine receptor α-subunit. Proc. Natl. Acad. Sci. USA. 96:1999;8086-8091.
107. Katz-Levy Y., Dayan M., Wirguin I., Fridkin M., Sela M., Mozes E. Single amino acid analogs of a myasthenogenic peptide modulate specific T cell responses and prevent the induction of experimental autoimmune myasthenia gravis. J. Neuroimmunol. 85:1998;78-86.
108. Araga S., LeBoeuf R. D., Blalock J. E. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor. Proc. Natl. Acad. Sci. USA. 90:1993;8747-8751.
109. Spack E. G., McCutcheon M., Corbelletta N., Nag B., Passmore D., Sharma S. D. Induction of tolerance in experimental autoimmune myasthenia gravis with solubilized MHC class II:acetylcholine receptor peptide complexes. J. Autoimmun. 8:1995;787-807.